Last month I posted a scheme for the synthesis of a late-stage intermediate towards AZD9833, a compound identified by AstraZeneca as a selective estrogen receptor degrader (SERD) and antagonist that is currently in phase 2b clinical trials for the treatment of ER+ breast cancer. I asked if you could identify reagents or intermediates A-C. Below are the answers! You can read more here in the full reference: J. Scott et al, J. Med. Chem. 2020, 63, 14530–14559
Identify the reagents 4: answers
Recent articles from the lab
Pulp Fiction
Written by John Studley, 7th May 2024 As most process chemists know (but perhaps not so many discovery chemists) DMSO is nasty material. It undergoes explosive autocatalytic decomposition at or near its boiling point (189°C) generating non-condensable gases and concomitant extremely rapid pressure increases that can rupture a reactor vessel like a knife through butter.…
Living in a “Material World”
Written by Jonathan Moseley, April 17th 2024 No relation to the Madonna song, but rather the title of a book by Ed Conway, an economist and journalist, regarding the Material World in which we live. And if like me, you have a general interest in chemistry, as well as some interest in economics and history…
Put and Take Shakes It Up
In this post I’m highlighting a couple of papers that are essentially two sides of the same coin. As a process chemist, I’ll be the first to admit that the chemistry I’m about to describe is not going to end up in your manufacturing route any time soon, but as a former card-carrying medicinal chemist…